RxDoctor Payments Data

Jenna Richey, NP

Adult Health · Depew, NYNPI 1184342719

Payments from drug & device makers

$592in general payments, 2019–2025

Across 19 payments — averaging $31.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$335
  • Exact Sciences$83
  • UCB, Inc.$45
  • GSK$38
  • Lilly USA, LLC$31
  • Pfizer$23
  • plus $36 from 2 others

What the payments were for

  • Food & beverage$592100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca8$335
Exact Sciences3$83
UCB, Inc.1$45
GSK2$38
Lilly USA, LLC2$31
Pfizer1$23
Novo Nordisk1$21
AbbVie1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$592 in reported general payments places this provider in the 55th percentile of 3,828 adult health providers in New York.

See all adult health providers in New York

Medicare billing

Part B allowed, 2024
$19,367
Medicare patients
135
Services billed
338

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide41$63,796
Trelegy ElliptaFluticasone/Umeclidin/Vilanter34$29,217
JardianceEmpagliflozin22$21,986
TrulicityDulaglutide22$21,698
MounjaroTirzepatide17$17,621
Breo ElliptaFluticasone/Vilanterol35$15,466
Breztri AerosphereBudesonide/Glycopyr/Formoterol15$11,742
Fluticasone-SalmeterolFluticasone Propion/Salmeterol23$5,105
Levothyroxine Sodium169$2,755
Albuterol Sulfate HfaAlbuterol Sulfate66$2,189
Fluticasone Propionate34$1,670
Potassium Chloride17$1,362
Atorvastatin Calcium115$1,351
Metoprolol Succinate66$1,175
Omeprazole73$1,150

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$21$63,79641 claims
GSKTrelegy Ellipta, Breo Ellipta$38$44,68369 claims
Lilly USA, LLCTrulicity, Mounjaro$31$39,31839 claims
AstraZenecaBreztri Aerosphere$335$11,74215 claims
AbbVieSynthroid$16$43815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 3,828 adult health providers in New York.

Other adult health in Depew

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →